Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin: 2016-2024

Historic FCF Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -25.40%.

  • Akebia Therapeutics' FCF Margin rose 6559.00% to 47.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.30%, marking a year-over-year decrease of 24705.00%. This contributed to the annual value of -25.40% for FY2024, which is 20844.00% up from last year.
  • Latest data reveals that Akebia Therapeutics reported FCF Margin of -25.40% as of FY2024, which was up 89.14% from -233.84% recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' FCF Margin registered a high of -25.05% during FY2022, and its lowest value of -233.84% during FY2023.
  • In the last 3 years, Akebia Therapeutics' FCF Margin had a median value of -25.40% in 2024 and averaged -94.76%.
  • Per our database at Business Quant, Akebia Therapeutics' FCF Margin surged by 260,339bps in 2020 and then plummeted by 20,879bps in 2023.
  • Over the past 5 years, Akebia Therapeutics' FCF Margin (Yearly) stood at -37.57% in 2020, then tumbled by 8,198bps to -119.55% in 2021, then surged by 9,450bps to -25.05% in 2022, then plummeted by 20,879bps to -233.84% in 2023, then spiked by 20,844bps to -25.40% in 2024.